Ltd - Hong Kong-based pharmaceutical company - Says new drug application for tazemetostat given priority review by the ...
Hutchmed (China) Limited 04 July 2024 Press Release HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of...
Hutchmed (China) Limited 28 June 2024 Press Release Overseas Regulatory Announcement: Filing of Form F-3 Hong Kong, Shanghai &...
Hutchmed (China) Limited 28 June 2024 Blocklisting Six Monthly Return Hong Kong, Shanghai, & Florham Park, NJ - Friday, June 28, 2024:...
Hutchmed (China) Limited 28 June 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ ¡X Friday, June 28, 2024: HUTCHMED...
Hutchmed (China) Limited 26 June 2024 HUTCHMED to Announce 2024 Half-Year Financial Results Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed (China) Limited 24 June 2024 Press Release Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 - HUTCHMED will...
Ltd - Hong Kong-headquartered biopharmaceutical company - Notes that Takeda Pharmaceuticals Co Ltd received a notifica ...
Hutchmed (China) Limited 24 June 2024 HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda ...
Hutchmed (China) Ltd on Monday said its phase 3 trial of sovleplenib showed "consistent benefits" in adults with auto ...
Hutchmed (China) Limited 17 June 2024 Press Release HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology...
Ltd - Hong Kong-headquartered biopharmaceutical company - Says that it has initiated Phase I clinical trial of its men ...
Hutchmed (China) Limited 07 June 2024 Press Release HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with...
Hutchmed (China) Limited 03 June 2024 Press Release HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine ...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.